Veranova has appointed Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides.

Villain brings extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space.

“Dr. Villain, and his holistic experience in the development and manufacturing of peptide APIs, will be a tremendous asset to Veranova,” says Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer. “We have great momentum right now following our ongoing investment in the bioconjugation sector as well as the recent groundbreaking of our HPAPI and ADC expansion in Devens. This additional investment in leading talent will support our growing presence in the TIDES space, in further support of our strategic initiatives and vision.”

Experience

Villain is an experienced Chemistry, Manufacturing, and Controls (CMC) leader, specializing in the full lifecycle management of peptide drug substances and their development. His expertise spans process development, scale-up, validation, cGMP manufacturing of peptide APIs, and regulatory compliance (ICH Q7A, Q11). He has a proven track record of introducing innovation and driving the successful manufacture and commercialization of peptide APIs.

The bulk of his 40-year career was spent with Bachem Americas Inc., where he held several senior leadership roles—initially as Vice President of Research and Development, then as Vice President of GMP Manufacturing, and finally as Vice President of CMC Development. In these roles, he led the development of over 60 peptide APIs and oversaw all peptide API manufacturing operations, ensuring cGMP compliance from early-stage development through commercial production. He also founded MV API Consulting and most recently served as Vice President and Global Peptides Technical Lead at Piramal Pharma Solutions.

Villain holds a Doctorate of Medicinal Chemistry and Pharmaceutical Science from the University of Milan (Università degli Studi di Milano) and has completed postdoctoral fellowships with The University of Alabama (Birmingham) and the University of Geneva (Switzerland). He has contributed his expertise to presentations and workshops for Tides USA and US Pharmacopeia (USP).